Zacks.com on MSN12d
Corcept Submits Application for Another Cushing's Syndrome DrugCORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
CORT’s sole marketed drug, Korlym (mifepristone), is already approved for treating Cushing's syndrome. The drug has been witnessing a strong demand in the past couple of quarters and the trend ...
The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive ...
Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the ...
Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...
The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive cortisol ...
The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback